Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg
Lupin Limited is a leading Indian multinational pharmaceutical company. It has established itself as a major player in the global healthcare industry. The company was founded by Desh Bandhu Gupta in 1968. It has grown into one of the largest generic pharmaceutical companies worldwide by revenue with decades of experience since its inception. The headquarters of the company is located in Mumbai, Maharashtra, India. Primary products of Lupin Limited include generic drugs, biosimilars, and specialty medicines. The company’s focus spans key therapeutic areas such as pediatrics and anti-tuberculosis treatments. Read More...
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 20,141.50 | 16,792.57 | 16,615.57 | 15,299.25 | 15,858.52 |
Total Expenses | 17,719.23 | 16,076.08 | 17,988.14 | 13,624.13 | 14,353.16 |
Profit Before Tax | 2,422.27 | 716.49 | -1,372.21 | 1,676.45 | 757.23 |
Profit After Tax | 1,935.57 | 447.69 | -1,509.36 | 1,227.93 | -399.88 |
Operating Profit after Depreciation | 2,733.88 | 990.79 | -1,229.80 | 1,815.76 | 1,868.34 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 9,055.16 | 8,698.41 | 7,680.43 | 8,095.48 | 8,119.57 |
Total Non Current Assets | 10,549.53 | 10,504.63 | 9,363.54 | 9,624.07 | 9,570.64 |
Total Current Assets | 13,447.65 | 12,451.30 | 12,457.68 | 13,986.37 | 15,413.21 |
TOTAL ASSETS | 23,997.18 | 22,955.93 | 21,821.22 | 23,610.44 | 24,983.85 |
Total Shareholder's Fund | 14,290.29 | 12,464.50 | 12,153.27 | 13,803.14 | 12,536.70 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 3,648.36 | 1,897.24 | 367.31 | 1,821.76 | 1,468.84 |
Net Cash used in Investing Activities | -1,712.20 | -1,286.77 | 1,292.23 | -1,239.58 | 1,106.99 |
Net Cash used in Financing Activities | -2,184.21 | -337.25 | -1,572.32 | -1,885.27 | -890.58 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 14,782.01 | 11,468.85 | 11,988.66 | 11,185.02 | 11,500.85 |
Total Expenses | 11,997.32 | 10,941.71 | 12,150.19 | 9,555.32 | 9,689.39 |
Profit Before Tax | 2,784.69 | 527.14 | -161.53 | 1,629.70 | 1,052.25 |
Profit After Tax | 2,326.09 | 425.21 | -188.70 | 1,258.62 | 727.55 |
Operating Profit after Depreciation | 2,841.04 | 625.58 | -88.06 | 1,670.32 | 1,864.05 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 4,147.88 | 4,210.53 | 3,863.88 | 3,793.86 | 3,641.25 |
Total Non Current Assets | 15,634.99 | 15,112.75 | 13,875.55 | 12,241.19 | 9,841.99 |
Total Current Assets | 9,287.87 | 7,570.92 | 8,437.82 | 9,617.37 | 10,838.51 |
TOTAL ASSETS | 24,922.86 | 22,683.67 | 22,313.37 | 21,858.56 | 20,680.50 |
Total Shareholder's Fund | 20,603.09 | 18,411.86 | 18,150.19 | 18,565.57 | 17,473.20 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 2,504.13 | 1,793.99 | 151.03 | 1,570.08 | 2,219.49 |
Net Cash used in Investing Activities | -1,599.02 | -1,269.17 | -371.79 | -2,507.52 | -739.56 |
Net Cash used in Financing Activities | -867.07 | -498.26 | 102.45 | -53.17 | -367.85 |
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 5,767.71 | 5,672.73 | 5,600.33 | 4,960.79 | 5,197.41 |
Total Expenses | 4,411.81 | 4,332.37 | 4,359.36 | 3,963.94 | 4,159.47 |
Profit Before Tax | 1,071.27 | 1,054.86 | 993.03 | 497.71 | 736.10 |
Profit After Tax | 858.86 | 859.48 | 805.54 | 368.22 | 618.70 |
Operating Profit after Depreciation | 1,409.61 | 1,382.65 | 1,308.75 | 1,026.10 | 1,067.31 |
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 4,208 | 4,106.20 | 4,167.63 | 3,395.88 | 4,115.75 |
Total Expenses | 2,796.95 | 2,991.45 | 2,967.96 | 2,695.53 | 2,898.41 |
Profit Before Tax | 1,217.06 | 984.05 | 1,082.92 | 428.16 | 1,083.96 |
Profit After Tax | 984.67 | 807.76 | 889.18 | 384.08 | 916.44 |
Operating Profit after Depreciation | 1,466.35 | 1,147.37 | 1,237.89 | 731.69 | 1,240.50 |
₹8/Share
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Lupin Ltd | ₹1,968.55 | ₹89,860.57 |
Sun Pharmaceuticals Industries Ltd | ₹1,704.65 | ₹4,09,002.64 |
Divis Laboratories Ltd | ₹5,836.45 | ₹1,54,939.41 |
Cipla Ltd | ₹1,459.05 | ₹1,17,834.93 |
Torrent Pharmaceuticals Ltd | ₹3,011.50 | ₹1,01,918.27 |
Dr Reddys Laboratories Ltd | ₹1,195.85 | ₹99,784.59 |
Lupin's consolidated net profit jumped 38.81% to Rs 858.86 crore on 10.60% increase in sales to Rs 5,618.6 crore in Q3 FY25 over Q3 FY24.
12 Feb 2025, 11:23 am
At meeting held on 11 February 2025
12 Feb 2025, 09:05 am
Used in treatment of pulmonary arterial hypertension in pediatric patients
10 Feb 2025, 03:48 pm
Lupin gained 3.66% to Rs 2,188 after the company announced that it has received a tentative approval from the U.S. Food and Drug Administration (USFDA) for its ANDA for Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide tablets.
05 Feb 2025, 12:57 pm
Lupin has announced that the the United States Food and Drug Administration (US FDA) has concluded the pre-approval inspection of the company's Edaravone Oral Suspension, located at its manufacturing facility in Somerset, New Jersey.
03 Feb 2025, 01:46 pm
View More